Kaushal Mohit 4
4 · Oncology Institute, Inc. · Filed Nov 16, 2021
Insider Transaction Report
Form 4
Kaushal Mohit
Director
Transactions
- Conversion
Class B Common Stock
2021-11-12−30,000→ 0 total→ Class A Common Stock (30,000 underlying) - Conversion
Common Stock
2021-11-12+30,000→ 30,000 total - Disposition to Issuer
Common Stock
2021-11-12−4,466→ 25,534 total
Footnotes (3)
- [F1]The shares of Class B common stock converted into shares of the Issuer's Class A common stock on a one for basis in connection with the Business Combination (as deifned below), and have no expiration date.
- [F2]On November 12, 2021, pursuant to that certain Agreement and Plan of Merger, dated as June 28, 2021, by and among DFP Healthcare Acqusitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination. In connection with the Business Combination, the Class A common stock was converted to Common Stock of the Issuer, pursuant to a reclassification exempt under Rule 16b-7.
- [F3]On November 12, 2021, in connection with the Business Combination, Mr. Kaushal, forfeited 4,466 of his shares of the Issuer's common stock to the Issuer pursuant to the Stockholder Support Agreement, dated as of June 28, 2021, by and among, DFP and TOI and certain DFP directors and officers, including Mr. Kaushal.